By Sabela Ojea

 

AstraZeneca PLC said Monday that its severe-asthma drug, Tezspire, has been approved in the U.S. after a priority review by the Food and Drug Administration.

The Anglo-Swedish pharmaceuticals company said that Tezspire has been approved for adults and children aged 12 years and older.

"It is the first and only biologic to consistently and significantly reduce asthma exacerbations across Phase two and three clinical trial," AstraZeneca said.

 

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

 

(END) Dow Jones Newswires

December 20, 2021 02:48 ET (07:48 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2022 até Mai 2022 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mai 2021 até Mai 2022 Click aqui para mais gráficos Astrazeneca.